• Publications
  • Influence
PD-1 blockade in tumors with mismatch repair deficiency.
  • J. Uram, Hao Wang, L. Diaz
  • Medicine, Biology
    Journal of clinical oncology : official journal…
  • 20 June 2015
TLDR
MM status predicts clinical benefit of immune checkpoint blockade with pembrolizumab, and high total somatic mutation loads were associated with PFS.
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
TLDR
Evaluating the efficacy of PD-1 blockade in patients with advanced mismatch repair–deficient cancers across 12 different tumor types showed that colorectal cancers with mismatch repair deficiency were sensitive to immune checkpoint blockade with antibodies to programmed death receptor–1 (PD-1).
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
  • D. Le, J. Uram, L. Diaz
  • Medicine, Biology
    The New England journal of medicine
  • 24 June 2015
TLDR
This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab, and high somatic mutation loads were associated with prolonged progression-free survival.
Hypersensitivity reactions from taxol.
TLDR
Hypersensitivity reactions to taxol have been one of the toxicities observed with administration of this drug and guidelines are provided to prevent or minimize such toxicity and treat reactions if they still occur.
Clinical toxicities encountered with paclitaxel (Taxol).
Although paclitaxel (TAXOL) appears to be one of the most promising antineoplastic agents of the last decade, with demonstrated activity in advanced and refractory ovarian, breast, lung, and head and
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
TLDR
Ipilimumab (anti-CTLA-4) has been tested as a single agent in patients with pancreatic ductal adenocarcinoma and in combination with GVAX has the potential for clinical benefit and should be evaluated in a larger study.
Paclitaxel (taxol)
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
TLDR
Results of this trial suggest a benefit for EGFR/HER1 blockade with erlotinib in patients with HCC manifested by disease control.
Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies
TLDR
It is concluded that sensory–motor neuropathy is a frequent dose‐dependent toxicity of combined cisplatin and taxol use and is likely to become the major dose‐limiting toxicity of taxol–cisplatin combination chemotherapy when higher doses of these agents are administered with granulocyte‐colony stimulating factor.
...
...